Keep a close eye on Pharmacyclics, Inc. (PCYC). The company reported an impressive 2015 U.S. net product revenue growth guidance, based on increased market penetration for its cancer treatment IMBRUVICA within its three approved indications due to continuing strong demand and an anticipated market expansion related to a pending fourth indication.
According to its preliminary unaudited results, PCYC expects for the fiscal year 2014 U.S. net product revenue for IMBRUVICA(R) of approximately $492 million. For the fourth quarter 2014, PCYC expects U.S. net product revenue of approximately $185 million, an approximately 31% increase compared to the previous quarter.
As of December 31, 2014, PCYC said that its unaudited balance of cash, cash equivalents and marketable securities is anticipated to be in excess of $850 million.
For 2015, PCYC anticipates U.S. net product revenue of approximately $1 billion for IMBRUVICA, representing a 103% increase over the expected 2014 U.S. net product revenue.
PCYC markets IMBRUVICA (ibrutinib), a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell receptor signaling complex that plays an important role in the survival and spread of malignant B cells. IMBRUVICA blocks signals that tell malignant B-cells to multiply and spread uncontrollably
PCYC is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
More about Pharmacyclics, Inc. (PCYC) at www.pharmacyclics.com.
**
Bovie Medical Corporation (BVX) reported that all J-Plasma(R) disposable hand pieces as well as the Bovie(R) Ultimate(TM) generator have received CE Mark approval for compliance with European Union safety, health and environmental protection requirements. As a result, BVX will be able to sell these devices in the 31 countries of the European Economic Area.
BVX also said that the December publication of a new white paper addresses the use of J-Plasma(R) in targeting the chronic pelvic pain of occult endometriosis sufferers compared with existing options including apparent lesion removal and the complete removal of the peritoneum.
The white paper highlighted benefits of using J-Plasma, including minimized lateral and depth of thermal spread, reduced healing times and reduced risk to vital structures such as the fallopian tubes and ovaries.
BVX is a leading maker of medical devices and supplies, as well as the developer of J-Plasma, a patented new plasma-based surgical product for cutting and coagulation. BVX's J-Plasma utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal thermal spread and an absence of conductive currents through the patient during surgery.
More about Bovie Medical Corporation (BVX) at www.boviemed.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet
The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included Santa Clarita ( www.santaclarita.crwe-pr.com ), the third largest city in Los Angeles County, California into the CRWE Network.
Santa Clarita is located in north Los Angeles County, about 35 miles (56 km) northwest of downtown Los Angeles, and occupies most of the Santa Clarita Valley. Home to Six Flags Magic Mountain and Hurricane Harbor, Santa Clarita boasts abundant sunshine, a unique blend of upscale sophistication and small town charm, historic elements, destination dining, signature shopping, golf, outdoor adventure, and a variety of world-class events, scenic drives, attractions and accommodations.
The City of Santa Clarita had an estimated population in 2013 (U.S. Census Bureau) of 179,590, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
According to its preliminary unaudited results, PCYC expects for the fiscal year 2014 U.S. net product revenue for IMBRUVICA(R) of approximately $492 million. For the fourth quarter 2014, PCYC expects U.S. net product revenue of approximately $185 million, an approximately 31% increase compared to the previous quarter.
As of December 31, 2014, PCYC said that its unaudited balance of cash, cash equivalents and marketable securities is anticipated to be in excess of $850 million.
For 2015, PCYC anticipates U.S. net product revenue of approximately $1 billion for IMBRUVICA, representing a 103% increase over the expected 2014 U.S. net product revenue.
PCYC markets IMBRUVICA (ibrutinib), a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell receptor signaling complex that plays an important role in the survival and spread of malignant B cells. IMBRUVICA blocks signals that tell malignant B-cells to multiply and spread uncontrollably
PCYC is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
More about Pharmacyclics, Inc. (PCYC) at www.pharmacyclics.com.
**
Bovie Medical Corporation (BVX) reported that all J-Plasma(R) disposable hand pieces as well as the Bovie(R) Ultimate(TM) generator have received CE Mark approval for compliance with European Union safety, health and environmental protection requirements. As a result, BVX will be able to sell these devices in the 31 countries of the European Economic Area.
BVX also said that the December publication of a new white paper addresses the use of J-Plasma(R) in targeting the chronic pelvic pain of occult endometriosis sufferers compared with existing options including apparent lesion removal and the complete removal of the peritoneum.
The white paper highlighted benefits of using J-Plasma, including minimized lateral and depth of thermal spread, reduced healing times and reduced risk to vital structures such as the fallopian tubes and ovaries.
BVX is a leading maker of medical devices and supplies, as well as the developer of J-Plasma, a patented new plasma-based surgical product for cutting and coagulation. BVX's J-Plasma utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal thermal spread and an absence of conductive currents through the patient during surgery.
More about Bovie Medical Corporation (BVX) at www.boviemed.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet
The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included Santa Clarita ( www.santaclarita.crwe-pr.com ), the third largest city in Los Angeles County, California into the CRWE Network.
Santa Clarita is located in north Los Angeles County, about 35 miles (56 km) northwest of downtown Los Angeles, and occupies most of the Santa Clarita Valley. Home to Six Flags Magic Mountain and Hurricane Harbor, Santa Clarita boasts abundant sunshine, a unique blend of upscale sophistication and small town charm, historic elements, destination dining, signature shopping, golf, outdoor adventure, and a variety of world-class events, scenic drives, attractions and accommodations.
The City of Santa Clarita had an estimated population in 2013 (U.S. Census Bureau) of 179,590, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
